Inhaled Corticosteroids and Bone Health
Open Access
- 31 January 2015
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Respiratory Medicine Journal
- Vol. 8 (1) , 85-92
Abstract
Inhaled corticosteroids (ICS) are the cornerstones in the management of bronchial asthma and some cases of chronic obstructive pulmonary disease. Although ICS are claimed to have low side effect profiles, at high doses they can cause systemic adverse effects including bone diseases such as osteopenia, osteoporosis and osteonecrosis. Corticosteroids have detrimental effects on function and survival of osteoblasts and osteocytes, and with the prolongation of osteoclast survival, induce metabolic bone disease. Glucocorticoid-induced osteoporosis (GIO) can be associated with major complications such as vertebral and neck of femur fractures. The American College of Rheumatology (ACR) published criteria in 2010 for the management of GIO. ACR recommends bisphosphonates along with calcium and vitamin D supplements as the first-line agents for GIO management. ACR recommendations can be applied to manage patients on ICS with a high risk of developing metabolic bone disease. This review outlines the mechanisms and management of ICS-induced bone disease.Keywords
This publication has 71 references indexed in Scilit:
- Osteonecrosis of the Femoral HeadJournal of the American Academy of Orthopaedic Surgeons, 2014
- Avascular necrosis in a HIV patient receiving ritonavir and inhaled fluticasoneInternational Journal of STD & AIDS, 2013
- European guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporosis International, 2012
- Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosisJournal of Bone and Mineral Research, 2011
- Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studiesThorax, 2011
- Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonatesAnnals of the Rheumatic Diseases, 2010
- Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged miceAging Cell, 2010
- The Use of Alendronate to Prevent Early Collapse of the Femoral Head in Patients with Nontraumatic OsteonecrosisA Randomized Clinical StudyJournal of Bone and Joint Surgery, 2005
- Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoidsThorax, 2004
- Apoptosis of Osteocytes in Glucocorticoid-Induced Osteonecrosis of the Hip1The Journal of Clinical Endocrinology & Metabolism, 2000